AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 18081359
Drug: hylan G‐F
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hylan G‐F 20
Trial: 10661482
Drug: rhEPO therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rhEPO therapy
Trial: 10661482
Drug: No rhEPO
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No rhEPO therapy
Trial: 10661482
Drug: Folic acid
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Folic acid supplementation (10 mg, 3 times a week)
Trial: 10661482
Drug: Comparison of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparison of controls and dialyzed patients on rhEPO therapy
Trial: 23452711
Drug: Emotional Freedom
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Emotional Freedom Technique (EFT), used twice a day for two months
Trial: 18848470
Drug: 1500 mg
RxNorm normalized name: inulin 1500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1500 mg of oral glucosamine sulphate once daily for 2 years
Trial: 18848470
Drug: Placebo once
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo once daily for 2 years
Trial: 17128343
Drug: Single-dose tinidazole
RxNorm normalized name: Tinidazole
DrugBank: Tinidazole (DB00911)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single-dose tinidazole plus fluconazole (TF)
Trial: 17128343
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment with metronidazole plus vaginal clotrimazole (MC)
Trial: 17128343
Drug: Single-dose tinidazole
RxNorm normalized name: Tinidazole
DrugBank: Tinidazole (DB00911)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single-dose tinidazole plus fluconazole (TF) among HIV-infected women
Trial: 17128343
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment with metronidazole plus vaginal clotrimazole (MC) among HIV-infected women
Trial: 17128343
Drug: Single-dose tinidazole
RxNorm normalized name: Tinidazole
DrugBank: Tinidazole (DB00911)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single-dose tinidazole plus fluconazole (TF) among HIV-uninfected women
Trial: 17128343
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment with metronidazole plus vaginal clotrimazole (MC) among HIV-uninfected women
Trial: 17128343
Drug: Single-dose tinidazole
RxNorm normalized name: Tinidazole
DrugBank: Tinidazole (DB00911)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single-dose tinidazole plus fluconazole (TF) followed by metronidazole plus vaginal clotrimazole (MC) as second-line treatment
Trial: 11721720
Drug: Intravenous diltiazem
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous diltiazem (10 mg bolus + 10 mg/hour for 3 days)
Trial: 8256988
Drug: Calcium supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium supplementation (1700 mg of calcium carbonate daily)
Trial: 8256988
Drug: Estrogen-progesterone-calcium (0.625
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Estrogen-progesterone-calcium (0.625 mg conjugated equine estrogens, 10 mg progesterone, and 1700 mg elemental calcium daily)
Trial: 3300974
Drug: isosorbide 5‐mononitrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: isosorbide 5‐mononitrate (acute administration)
Trial: 3300974
Drug: isosorbide 5‐mononitrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: isosorbide 5‐mononitrate (2 months treatment, 20 mg three times daily)
Trial: 3300974
Drug: placebo (acute
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo (acute administration)
Trial: 31914620
Drug: Exercise twice-a-day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exercise twice-a-day
Trial: 31914620
Drug: Once-daily exercise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-daily exercise
Trial: 16681817
Drug: Luliconazole 1%
RxNorm normalized name: LULICONAZOLE 1% CREAM,TOP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Luliconazole 1% cream applied once a day for 2 weeks, followed by placebo for 2 weeks.
Trial: 16681817
Drug: Bifonazole 1%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bifonazole 1% cream applied once a day for 4 weeks.
Trial: 16681817
Drug: Luliconazole 1%
RxNorm normalized name: LULICONAZOLE 1% CREAM,TOP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Luliconazole 1% cream
Trial: 24684520
Drug: Mindfulness-based cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mindfulness-based cognitive therapy (8-week treatment as an adjunct to usual psoriasis therapy)
Trial: 24684520
Drug: Usual psoriasis
RxNorm normalized name: MG 217 Psoriasis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual psoriasis therapy alone (Control group)
Trial: 23427387
Drug: Jiutengzhuyu tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Jiutengzhuyu tablets taken orally for 25 days
Trial: 23427387
Drug: Intrauterine infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intrauterine infusion of 5 mg dexamethasone sodium phosphate, 4000 units of chymotrypsin, 80,000 units of gentamicin sulfate in 20 mL normal saline at 1 mL/min
Trial: 19155999
Drug: Paclitaxel (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paclitaxel (100 mg/m(2) d(1), d(8), d(15)) plus gemcitabine (1250 mg/m(2) d(1) and d(8), every 4 weeks) - Arm B
Trial: 19155999
Drug: Cisplatin (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisplatin (75 mg/m(2), d(1)) and gemcitabine (1250 mg/m(2), d(1) and d(8), every 3 weeks) - Arm A
Trial: 11822009
Drug: Expandable metal
RxNorm normalized name: menthone 1,2-glycerol ketal, (-)-
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Expandable metal stents or ablative therapy
Trial: 9846778
Drug: Gabapentin (maximum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gabapentin (maximum dosage of 3600 mg/d)
Trial: 24593836
Drug: Supragingival scaling
RxNorm normalized name: wing scale pollen extract
DrugBank: Atriplex canescens pollen (DB10767)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supragingival scaling treatment
Trial: 22172433
Drug: LibiGel (low-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LibiGel (low-dose testosterone gel)
Trial: 20823282
Drug: Raltegravir 400
RxNorm normalized name: raltegravir 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Raltegravir 400 mg twice daily (arm A)
Trial: 20823282
Drug: Raltegravir 400
RxNorm normalized name: raltegravir 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Raltegravir 400 mg plus atazanavir 400 mg once daily (arm B)
Trial: 16395096
Drug: MMRV vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MMRV vaccine (2 doses, 6-8 weeks apart)
Trial: 16395096
Drug: MMR+V group
RxNorm normalized name: Penicillin V
DrugBank: Phenoxymethylpenicillin (DB00417)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: MMR+V group (1 dose of MMR and 1 dose of varicella, followed by a second dose of MMR at 6-8 weeks later)
Trial: 16395096
Drug: MMRV vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MMRV vaccine (after first dose)
Trial: 16395096
Drug: MMR+V group
RxNorm normalized name: Penicillin V
DrugBank: Phenoxymethylpenicillin (DB00417)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: MMR+V group (after first dose)
Trial: 16395096
Drug: MMRV vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MMRV vaccine (after second dose)
Trial: 16395096
Drug: MMR+V group
RxNorm normalized name: Penicillin V
DrugBank: Phenoxymethylpenicillin (DB00417)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: MMR+V group (after second dose)
Trial: 8622612
Drug: Intravenous endothelin-1
RxNorm normalized name: nitric oxide synthase endothelial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous endothelin-1
Trial: 8622612
Drug: Oral nifedipine
RxNorm normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral nifedipine (10 mg) pretreatment before endothelin-1 infusion
Trial: 26319955
Drug: Peppermint oil
RxNorm normalized name: Peppermint Oil
DrugBank: Peppermint oil (DB11198)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peppermint oil (PO) 3 times daily for 4 weeks
Trial: 26319955
Drug: Placebo 3
RxNorm normalized name: placebo 330 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo 3 times daily for 4 weeks
Trial: 25694037
Drug: MK-7 (180
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK-7 (180 µg MenaQ7/day)
Trial: 15696079
Drug: Zafirlukast, 80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zafirlukast, 80 mg twice daily for 6 weeks
Trial: 12854927
Drug: Dinoprostone vaginal
RxNorm normalized name: dinoprostone Vaginal Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dinoprostone vaginal insert (10 mg every 12 h for a maximum of 24 h)
Trial: 10543411
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg glibenclamide
Trial: 8911107
Drug: High-dose chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose chemotherapy regimen (CTC) incorporating cyclophosphamide, thiotepa, and carboplatin with autologous PBSC support.
Trial: 8911107
Drug: High-dose chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose chemotherapy regimen (CTC) with autologous PBSC support.
Trial: 26707418
Drug: Medical therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medical therapy (Travoprost 0.004%)
Trial: 24754066
Drug: Adequate eradication
RxNorm normalized name: Adequan
DrugBank: Polysulfated glycosaminoglycan (DB11538)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adequate eradication therapy during treatment for CHD
Trial: 24754066
Drug: Antisecretory therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antisecretory therapy
Trial: 24754066
Drug: Treatment for
RxNorm normalized name: Hair Regrowth Treatment For Men
DrugBank: Minoxidil (DB00350)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Treatment for CHD only
Trial: 10169531
Drug: Zileuton 600
RxNorm normalized name: zileuton 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zileuton 600 mg QID
Trial: 10169531
Drug: Zileuton 600
RxNorm normalized name: zileuton 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zileuton 600 or 800 mg TID
Trial: 10169531
Drug: Zileuton 600
RxNorm normalized name: zileuton 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zileuton 600 or 800 mg BID
Trial: 29164421
Drug: Ribociclib (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ribociclib (600 mg/day; 3 weeks-on/1 week-off) plus letrozole (2.5 mg/day; continuous)
Trial: 29164421
Drug: Placebo plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo plus letrozole (2.5 mg/day; continuous)
Trial: 26408375
Drug: Combined oral
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined oral contraceptives (COCs) with doxycycline 40 mg
Trial: 22170412
Drug: Meloxicam (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meloxicam (10 mg once daily)
Trial: 16080277
Drug: Gemfibrozil 900
RxNorm normalized name: gemfibrozil 900 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemfibrozil 900 mg tablet (test formulation)
Trial: 16080277
Drug: Gemfibrozil 900
RxNorm normalized name: gemfibrozil 900 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemfibrozil 900 mg tablet (reference formulation)
Trial: 11821720
Drug: Nifedipine GITS
RxNorm normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nifedipine GITS (30-60 mg)
Trial: 8543496
Drug: Comparator agents
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparator agents (cephalosporins, imipenem/cilastatin)
Trial: 1771090
Drug: 75 mg
RxNorm normalized name: talc 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75 mg amitriptyline + 3 mg flupentixol
Trial: 28688622
Drug: Atorvastatin 20mg
RxNorm normalized name: AMLODIPINE 5MG/ATORVASTATIN 20MG TAB
DrugBank: Atorvastatin (DB01076)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Atorvastatin 20mg daily for 10 days (n=21)
Trial: 28688622
Drug: Placebo 20mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo 20mg daily for 10 days (n=23)
Trial: 20435692
Drug: Metformin (BMI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin (BMI > 32 kg/m(2))
Trial: 20435692
Drug: Metformin (BMI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin (BMI < or = 32 kg/m(2))
Trial: 20435692
Drug: Clomiphene citrate
RxNorm normalized name: Clomiphene Citrate
DrugBank: Clomifene (DB00882)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clomiphene citrate (CC) (BMI < or = 32 kg/m(2))
Trial: 20435692
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of Metformin plus CC (BMI < or = 32 kg/m(2))
Trial: 16237140
Drug: Protocol B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protocol B (CT at 90 kV with 100 mL contrast material)
Trial: 16237140
Drug: Protocol C
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protocol C (CT at 90 kV with 80 mL contrast material)
Trial: 16237140
Drug: Protocol A
RxNorm normalized name: Olay Professional Acne Protocol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protocol A (CT at 120 kV with 100 mL of contrast material)
Trial: 12394963
Drug: Inhaled nitrogen
RxNorm normalized name: nitrogen Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled nitrogen oxide
Trial: 2262581
Drug: Commercially available
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Commercially available toothpaste and gel products
Trial: 31324862
Drug: Pyridostigmine 0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pyridostigmine 0.25 mg/kg
Trial: 22198441
Drug: Citalopram plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Citalopram plus omega-3 fatty acids (900 mg eicosapentaenoic acid, 200 mg docosahexaenoic acid, 100 mg other omega-3 fatty acids, two 1 g capsules twice daily)
Trial: 22198441
Drug: Citalopram plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Citalopram plus placebo (olive oil, two 1 g capsules per day)
Trial: 20528992
Drug: 1% silver
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% silver sulfadiazine, changed daily
Trial: 12369079
Drug: Drug treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug treatment for capsaicin-induced coughing
Trial: 9713448
Drug: L‐NAME 54
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L‐NAME 54 mg
Trial: 9713448
Drug: L‐NAME 170
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L‐NAME 170 mg
Trial: 7868876
Drug: Placebo (1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (1.5 ml/min saline) during exercise test
Trial: 30575490
Drug: Modified FOLFIRINOX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified FOLFIRINOX regimen (oxaliplatin 85 mg/m², irinotecan 180 mg/m², leucovorin 400 mg/m², fluorouracil 2400 mg/m² every 2 weeks for 24 weeks)
Trial: 30575490
Drug: Gemcitabine (1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemcitabine (1000 mg/m² on days 1, 8, and 15 every 4 weeks for 24 weeks)
Trial: 27056608
Drug: Intravenous ketamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous ketamine (0.5 mg/kg of body weight), administered over 40 minutes, twice weekly for up to 4 weeks
Trial: 27056608
Drug: Intravenous ketamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous ketamine (0.5 mg/kg of body weight), administered over 40 minutes, thrice weekly for up to 4 weeks
Trial: 27056608
Drug: Intravenous placebo,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous placebo, administered over 40 minutes, twice weekly for up to 4 weeks
Trial: 27056608
Drug: Intravenous placebo,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous placebo, administered over 40 minutes, thrice weekly for up to 4 weeks
Trial: 27056608
Drug: Open-label ketamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Open-label ketamine (0.5 mg/kg of body weight), twice weekly
Trial: 27056608
Drug: Open-label ketamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Open-label ketamine (0.5 mg/kg of body weight), thrice weekly
Trial: 18762639
Drug: Operative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Operative treatment for upper lumbar herniations (L2-L3 or L3-L4)
Trial: 18762639
Drug: Operative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Operative treatment for L5-S1 herniations
Trial: 18762639
Drug: Operative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Operative treatment for L4-L5 herniations
Trial: 10535720
Drug: Imidapril (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imidapril (5 mg daily for 3 to 6 months)
Trial: 8767243
Drug: MAP maintained
RxNorm normalized name: phenazopyridine
DrugBank: Phenazopyridine (DB01438)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: MAP maintained above 70 mmHg using norepinephrine infusion (Group 2)
Trial: 26848137
Drug: 100-300 mg
RxNorm normalized name: orchard grass pollen extract
DrugBank: Dactylis glomerata pollen (DB10379)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100-300 mg volanesorsen
Trial: 24293339
Drug: Pharmaceutical care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical care (n = 315)
Trial: 16947035
Drug: Patient evaluation
RxNorm normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient evaluation of treatment success
Trial: 11463600
Drug: Low-dose theophylline
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose theophylline (250 mg twice per day)
Trial: 9875685
Drug: Once-daily tobramycin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-daily tobramycin (4 mg/kg/day)
Trial: 9875685
Drug: Twice-daily tobramycin
RxNorm normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Twice-daily tobramycin (4 mg/kg/day)
Trial: 7742607
Drug: Higher dose
RxNorm normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher dose rate brachytherapy
Trial: 7742607
Drug: Lower dose
RxNorm normalized name: flowers
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lower dose rate brachytherapy
Trial: 17392726
Drug: Remifentanil 0.15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil 0.15 mcg/kg/min
Trial: 30855722
Drug: Remifentanil 0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil 0.3 mcg/kg/min
Trial: 28904310
Drug: Botulinum toxin
RxNorm normalized name: Botulinum toxin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Botulinum toxin (BTX) type A injections
Trial: 21536199
Drug: Conservative therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conservative therapy (control group)
Trial: 23358983
Drug: Ciprofloxacin (750
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciprofloxacin (750 mg twice daily) plus Amoxicillin/Clavulanic acid (1,000 mg twice daily)
Trial: 23358983
Drug: Both arms
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both arms (Moxifloxacin and Combination Therapy)
Trial: 21538382
Drug: Trimetazidine (TMZ)
RxNorm normalized name: trimetazidine
DrugBank: Trimetazidine (DB09069)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trimetazidine (TMZ) monotherapy
Trial: 19135286
Drug: Cholera vaccine
RxNorm normalized name: Cholera Vaccine
DrugBank: Vibrio cholerae CVD 103-HgR strain live antigen (DB14443)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cholera vaccine coverage in the neighborhood
Trial: 17587254
Drug: Weekly injected
RxNorm normalized name: elagolix
DrugBank: Elagolix (DB11979)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Weekly injected subcutaneous interferon (IFN)‐beta‐1a 22 microg
Trial: 15822545
Drug: Constraint-induced movement
RxNorm normalized name: constant albicans extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Constraint-induced movement therapy (CIMT), 6 hours daily training for 2 weeks
Trial: 15822545
Drug: Conservative treatment,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conservative treatment, bimanual-upper-extremity training for 2 weeks
Trial: 10896237
Drug: Manual dosing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Manual dosing using a locally defined algorithm
Trial: 4028632
Drug: Oral activated
RxNorm normalized name: activated charcoal Oral Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral activated charcoal (180 gm) in divided doses over 24 hours
Trial: 27499018
Drug: Taliglucerase alfa
RxNorm normalized name: Taliglucerase alfa
DrugBank: Taliglucerase alfa (DB08876)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Taliglucerase alfa dose adjusted
Trial: 28132725
Drug: Lower protein
RxNorm normalized name: protein C
DrugBank: Protein C (DB11312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lower protein intake (g/kg/day)
Trial: 26687836
Drug: Standard-dose imatinib
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-dose imatinib
Trial: 17452544
Drug: Statin therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Statin therapy post-AMI
Trial: 8665034
Drug: FK224 (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FK224 (4 mg)
Trial: 2062984
Drug: d-amphetamine 30
RxNorm normalized name: dextroamphetamine
DrugBank: Dextroamphetamine (DB01576)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: d-amphetamine 30 mg